Company news

OSE Immunotherapeutics SA news in 2025

OSE Immunotherapeutics SA's news releases, calls and decks from 2025, newest first.

View company

OSE Immunotherapeutics Unveils 2026–2028 Strategic Plan With Four Opportunities for Value Creation

December 9, 2025

OSE Immunotherapeutics Announces Strategic Amendment to AbbVie’s Partnership on ABBV-230 Development

December 8, 2025

OSE Immunotherapeutics Announces Positive Recommendation from Independent Data Monitoring Committee (IDMC) to Continue Pivotal Phase 3 ARTEMIA Trial Evaluating Tedopi® in Non-Small Cell Lung Cancer

November 17, 2025

OSE Immunotherapeutics Reports First Half 2025 Financial Results

October 15, 2025

Appointment of Marc Le Bozec as Interim CEO

October 3, 2025

Full renewal of the Board of Directors Election of Dr. Markus Cappel as Chairman of the Board of Directors

September 30, 2025

OSE Immunotherapeutics, Inserm Transfert and Nantes University Announce Strategic Partnership to Accelerate Innovation in Immunotherapy

September 26, 2025

OSE Immunotherapeutics publie sa position de trésorerie au 30 juin 2025

September 25, 2025

Correction of a Material Error Relating to the Total Number of Voting Rights and Shares Comprising the Share Capital

September 24, 2025

OSE Immunotherapeutics acknowledges the decision of the Nantes Commercial Court

September 23, 2025

Two International Proxy Advisory Firms Support the Governance Project Proposed by OSE Immunotherapeutics at the September 30th General Meeting

September 22, 2025

Update on Information Relating to the General Meeting of September 30, 2025

September 12, 2025

OSE Immunotherapeutics and the FoRT Foundation Announce Completion of Enrollment in Combi-TED, a Phase 2 Clinical Trial Evaluating Tedopi® in Combination with Nivolumab or Docetaxel in Patients with Non-Small Cell Cancer

September 11, 2025

OSE Immunotherapeutics Board Urges Support for Value-Driving Strategy and Open-Minded Governance - Publication of Circular for Combined Annual General Meeting of September 30, 2025

September 9, 2025

OSE Immunotherapeutics: A Clear Strategy, Balanced Governance, and a Firm Course toward Value Creation

September 4, 2025

OSE Immunotherapeutics Reaffirms its Strategic Priorities and Publishes Shareholder Q&A to Restore Information Ahead of AGM

August 29, 2025

OSE Immunotherapeutics Proposes Governance Evolution and Reaffirms Strategic Priorities ahead of Annual General Meeting

August 25, 2025

OSE Immunotherapeutics Appoints Thomas Gidoin as Chief Financial Officer

August 20, 2025

OSE Immunotherapeutics lance une Newsletter pour les investisseurs individuels

July 17, 2025

OSE Immunotherapeutics met à jour l’information sur les procédures en cours

July 2, 2025

OSE Immunotherapeutics Publishes Letter to Shareholders

June 30, 2025

OSE Immunotherapeutics provides an update on ongoing proceedings

June 25, 2025

OSE Immunotherapeutics Reaffirms Commitment to Holding a Transparent and Serene General Meeting in Compliance with Market Rules

June 20, 2025

Adjournment of the general meeting initally convened on June 25, 2025

June 11, 2025

Update on the terms of the shareholders general meeting

June 9, 2025

OSE Immunotherapeutics strengthens Growth Strategy: Accelerates key pillars of Inflammation and Immuno-Oncology

June 4, 2025

Documents made available to the shareholders for the combined general meeting of June 25th, 2025

June 4, 2025

OSE Immunotherapeutics Provides Clinical Updates on Neo-Epitope Based Cancer Vaccine Tedopi® in Pancreatic Cancer and Non-Small Cell Lung Cancer

June 2, 2025

OSE Immunotherapeutics Announces that its Partner Boehringer Ingelheim Will Present Early Clinical Evidence of Innate Immune Modulation and Anti-Tumor Activity via SIRPα Blockade in Two Ongoing Trials at ASCO 2025

May 23, 2025

OSE Immunotherapeutics Announces Strategic Collaboration to Pioneer Novel mRNA Technologies

May 21, 2025

OSE Immunotherapeutics Announces >90% of Responders Maintained Symptomatic Remission Through Extension Period on Lusvertikimab

May 5, 2025

Decks in 2025